Celsion (NASDAQ:CLSN) Trading 10.3% Higher

Shares of Celsion Co. (NASDAQ:CLSN) traded up 10.3% on Thursday . The company traded as high as $1.80 and last traded at $1.71, 232,460 shares traded hands during mid-day trading. An increase of 93% from the average session volume of 120,287 shares. The stock had previously closed at $1.55.

A number of research analysts have recently weighed in on the company. Brookline Capital Management reissued a “buy” rating on shares of Celsion in a research note on Thursday, July 25th. Zacks Investment Research raised Celsion from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research note on Tuesday, August 20th. Finally, ValuEngine raised Celsion from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st.

The firm has a market cap of $37.43 million, a price-to-earnings ratio of -2.57 and a beta of 1.90. The company has a current ratio of 3.47, a quick ratio of 3.47 and a debt-to-equity ratio of 0.58. The company has a 50 day moving average of $1.75 and a 200 day moving average of $1.92.

Celsion (NASDAQ:CLSN) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.29) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. The business had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative return on equity of 53.40% and a negative net margin of 1,489.20%. Equities analysts forecast that Celsion Co. will post -1.09 EPS for the current fiscal year.

A hedge fund recently raised its stake in Celsion stock. Vanguard Group Inc. increased its holdings in shares of Celsion Co. (NASDAQ:CLSN) by 43.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 704,651 shares of the biotechnology company’s stock after buying an additional 211,779 shares during the quarter. Vanguard Group Inc. owned 3.44% of Celsion worth $1,282,000 as of its most recent SEC filing. 5.53% of the stock is currently owned by institutional investors and hedge funds.

About Celsion (NASDAQ:CLSN)

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.

See Also: What is a Lock-Up Period?

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.